LAUSR

A fundamental challenge facing the cervical screening community is how to risk-stratify or "triage" high-risk HPV infection optimally. Although most countries that have implemented HPV molecular screening recommend cytology and/or limited genotyping of HPV 16/18, neither of these approaches offer a solution which permits an HPV-positive-triage-negative women to return to routine recall, particularly as routine recall timeframes within HPV based programmes often stretch to 5 years (1).